EQA round: KD1/24 - Glycated Haemoglobin

Deadline: 26.1.2024

Setup: groups - R (manufacturer of kit); minimal size of the groups n = 5

RoM = robust average	AV = assigned value
SD = standard deviation	CVP = consensus of all participants
CV = coefficient of variation	U_{AV} = expanded uncertainty of the assigned value (k = 2)
N_{tot} = total number of the results	
N_{out} = number of the results removed before calculation	

D_{max} = acceptable difference	
LL = lower limit	
UL = upper limit	
N_{eva} = number of the results assessed	
N_{suc} = number of successful results	
S_{rel} = relative success	

Test Sample Group	[unit]	RoM	SD	CV [%]	N_{tot}	N_{out}		AV	U_{AV}	D_{max}	LL	UL	N_{eva}	N_{suc}	S_{rel} [%]
(220) Haemoglobin A$_{1c}$	[mmol/mol]				165								165	158	96
Sample A		43,6	1,8	4,2	165		CVP	43,6	0,35	10%	39,2	48	165	161	98
(1) Abbott		42	1,5	3,5	5	0							5		
(14) Bio-Rad		43,7	1,6	3,7	43	0							43		
(25) TOSOH		44,6	1,1	2,5	49	0							49		
(60) Roche		44,5	2,4	5,5	14	0							14		
(150) Arkray		42,4	1,4	3,4	47	0							47		
Other					7	0							7		
							1x 12, 2x 34, 1x 46, 2x 58, 1x 162								
Sample B		60,1	2,6	4,3	165		CVP	60,1	0,5	10%	54	66,2	165	160	97
(1) Abbott		59,5	0,74	1,2	5	0							5		
(14) Bio-Rad		60,9	2,6	4,3	43	0							43		
(25) TOSOH		60,6	1,2	1,9	49	0							49		
(60) Roche		63,2	2,3	3,6	14	0							14		
(150) Arkray		58	2	3,5	47	0							47		
Other					7	0							7		
							1x 12, 2x 34, 1x 46, 2x 58, 1x 162								